Shortly after completing a €36 million funding round, DISCO Pharmaceuticals GmbH has sent a further strategic signal by entering into an exclusive licence agreement with Amgen to develop novel cancer therapies targeting cell-surface structures. The collaboration is also likely to boost the company’s visibility on the international stage, not least in the context of the JP Morgan Healthcare Conference, currently bringing the global life sciences community together in San Francisco.
Under the agreement, Amgen will receive worldwide…
